The market for minimally invasive neurosurgical devices is expected to grow steadily as new clinical evidence supports the shift away from open craniotomy toward less invasive procedures. These devices are gaining attention for their potential to improve outcomes in treating intracranial haemorrhage (ICH) and brain tumours, although minimally invasive techniques have not yet become the standard of care for ICH. As more clinical trials demonstrate positive results and professional guidelines are updated, their usage is expected to increase over the coming years, say GlobalData, a leading data and analytics company.

According to GlobalData’s forecast, the global minimally invasive neurosurgical devices market is projected to grow at a compound annual growth rate (CAGR) of 6% from 2024 to 2034. Disposable handpieces are expected to grow at 10%, led by side-cutting aspiration disposable handpieces at 16%, while subcortical access devices are projected to increase at 14%. Ultrasonic aspiration disposable tips are currently the largest device type category by market value, about twice the size of the disposable handpiece segment in 2024.

North America is forecast to record the strongest growth during the period, followed by Asia-Pacific (APAC). Stryker Corp currently holds the largest global market share and leads in North America, South Central America, and Europe. The APAC and the Middle East and Africa are currently dominated by various medical device companies, although Stryker Corp also holds a substantial share in those regions.

Thomas Fleming, Medical Analyst at GlobalData, comments: “Reimbursement remains a key consideration for market growth. Following the publication of favourable trial results, devices used in minimally invasive neurosurgery are expected to receive higher incidents of government reimbursement. However, without reimbursement, the high cost of disposable components, such as handpieces, tips, and access devices, can limit their use, particularly in cost-sensitive markets. In some developing regions, these components are sometimes reprocessed and reused to reduce expenses.”

At present, treatments for ICH range from medication and supportive care to conventional open surgery. Among minimally invasive options, ultrasonic aspiration systems are the most established and are viewed by Key Opinion Leaders (KOLs) as the current standard for minimally invasive surgeries. Their broad applicability and proven safety record have supported their continued use. KOLs also indicate that continued clinical trial outcomes will likely encourage wider adoption of minimally invasive neurosurgery devices.

Fleming concludes: “As clinical trial results release, and government reimbursement frameworks improve, the minimally invasive neurosurgical devices market is positioned for substantial growth.”